Introduction
============

*Staphylococcus aureus* is a gram-positive bacterium, the most commonly isolated bacterial human pathogen \[[@b1-cm-91-7]\]. Although *Staphylococcus aureus* is considered an opportunistic pathogen, there are clones which can cause invasive disease, due to the presence of virulence factors that increase their chance of gaining access to normally sterile sites \[[@b2-cm-91-7]\].

In 1961, soon after the introduction of methicillin, strains of *Staphylococcus aureus* that were resistant were identified in the United Kingdom \[[@b3-cm-91-7]\] and were called Methicillin-resistant *Staphylococcus aureus* - MRSA. Until the year 1990, MRSA became endemic in university hospitals in the United States, particularly in Intensive Care Units \[[@b4-cm-91-7]\]. Since the 1990s, there has been an explosion of MRSA infections in populations with no risk of exposure to the health care system - later called community-acquired methicillin-resistant *Staphylococcus aureus* (CA-MRSA) \[[@b5-cm-91-7]\], first reported in Australia and the United States \[[@b6-cm-91-7]\].

There have been multiple attempts at differentiating of CA-MRSA from health care-associated MRSA (HA-MRSA). Clinically, CA-MRSA infection is defined as any MRSA infection diagnosed in an outpatient or within 48 h of hospitalization if the patient lacks the following HA-MRSA risk factors: haemodialysis, surgery, residence in a long-term-care facility. or hospitalization during the previous year, the presence of an indwelling catheter or percutaneous device at the time of culture, or previous isolation of MRSA from the patient \[[@b7-cm-91-7],[@b8-cm-91-7]\]. However, clinical distinction between CA-MRSA and HA-MRSA remains difficult \[[@b9-cm-91-7]\].

CA-MRSA strains differ from HA-MRSA strains in their molecular characteristics.

HA-MRSA strains have a relatively large mobile genomic island, Staphylococcal Chromosomal Cassette (SCCmec), belonging to type I, II, or III. These cassettes contain the mecA gene, which is nearly universal among MRSA isolates and is responsible for resistance to antibiotics. HA-MRSA are resistant to many classes of non-β-lactam antimicrobials. HA-MRSA has seldom the genes Panton-Valentine leukocidin (PVL) \[[@b4-cm-91-7],[@b10-cm-91-7]\].

CA-MRSA carry smaller SCCmec elements, type IV or type V. These smaller elements carry the mecA gene and are more mobile. They are resistant to fewer non-β-lactam classes of antimicrobials and frequently carry PVL genes \[[@b4-cm-91-7]\]. CA-MRSA clones are known to be more virulent than HA-MRSA \[[@b11-cm-91-7]\].

CA-MRSA affect previously healthy younger patients and can cause necrotizing pneumonia and severe sepsis. HA-MRSA affect people who are exposed to the health care setting, older patients with comorbidities, through pneumonia, bacteremia, and invasive infections \[[@b4-cm-91-7]\].

Given the complex epidemiology of CA-MRSA strains in hospital and the circulation of HA-MRSA strains in the community, a clear delineation between CA-MRSA and HA-MRSA strains is not possible \[[@b4-cm-91-7]\].

We describe the most important CA-MRSA clones that circulate nowadays in the world: the main molecular and epidemiological characteristics, as well as notions related to the clinic of infections produced by these clones and their antibiotic resistance spectrum.

The main clones of CA-MRSA in the world
=======================================

Multilocus sequence typing reveals a highly clonal structure for Staphylococcus aureus. Comparison of commensal and pathogenic strains shows no difference in diversity or clonal assignments, phage dynamics and global transcriptome shifts are considered responsible for the pathogenicity \[[@b12-cm-91-7]\].

Beginning in 1993, the MRSA infections of patients lacking health care-associated risk factors were reported from six continents, in diverse regions. Molecular evidence supports that CA-MRSA clones have arisen in the community by the horizontal transfer of SCCmec elements and PVL genes, as well as perhaps other virulence and resistance factors, to the genomes of MRSA strains. Thus, CA-MRSA strains developed in several decades of complex evolution \[[@b2-cm-91-7]\].

Experimental studies show recombination to have negligible impact on the diversification of the core genome of this species. the vast majority of clonal variants arise by point mutation. Recombination combined with demographic mechanisms and selection favor the rapid creation of new clonal complexes \[[@b13-cm-91-7]\].

North America
-------------

CA-MRSA epidemic in the United States is attributable to rise of a clone, referred to as USA300 -- ST8-IV ([Figure 1](#f1-cm-91-7){ref-type="fig"}), a virulent and easily transmissible strain of MRSA. It most commonly causes skin infections, but also necrotizing pneumonia or endocarditis \[[@b14-cm-91-7],[@b15-cm-91-7]\].

A recent study shows that United States households represent a frequent site of transmission and a long-term reservoir of USA300 strains; individuals within households transmit the same USA300 strain among themselves. A large proportion of the USA300 isolates in this study sequenced are resistant to fluoroquinolone \[[@b15-cm-91-7]\].

Military are at increased risk for MRSA skin and soft tissue infection. A study shows there is a transmission of MRSA among military trainees and suggests a long-term reservoir for MRSA in this setting \[[@b16-cm-91-7]\].

USA300 emerge first in community and then in healthcare settings. Most USA300 retain typical susceptibility profiles, but multidrug-resistant phenotypes are emerging. This clone is disseminated on every continent, except Antarctica \[[@b4-cm-91-7]\].

The epidemiology of MRSA in North America is much better studied and described than the European one.

Australia
---------

The percentage of MRSA has increased from 10.3% in 2000 to 16% in 2006. This increase has occurred throughout Australia and has been due to CA-MRSA clones. The predominate clone is Queensland (Qld) MRSA (ST93-IV) -- [figure 1](#f1-cm-91-7){ref-type="fig"}, a Panton-Valentine leukocidin (PVL) positive MRSA, the same as USA300. With transmission of Qld MRSA throughout the country, an increase in skin and soft tissue infections will occur in young Australians \[[@b17-cm-91-7]\]. In Western Australia, ST835 CA-MRSA is isolated almost exclusively from elderly care facilities \[[@b18-cm-91-7]\].

Europe
------

The prevalence of CA-MRSA in Europe seems to be less, especially in the Nordic countries \[[@b19-cm-91-7]\]. In Greece, rates of CA-MRSA in some centers approach those of North America. In contrast to North America, CA-MRSA in Europe is characterized by bigger clonal heterogeneity. The predominant European clone is ST80-IV ([Figure 1](#f1-cm-91-7){ref-type="fig"}), resistant to kanamycin/amikacin and fusidic acid \[[@b20-cm-91-7]--[@b21-cm-91-7]\], strongly associated with skin and soft tissue infections, rarely found among asymptomatic carriers. ST80 was first reported in 1993, but was relatively rare until the late 1990s \[[@b22-cm-91-7]\].

Phylogenetic analyses strongly suggest that the European epidemic CA-MRSA lineage is derived from a PVL-positive MRSA ancestor from sub-Saharan Africa. The tree topology suggests a single acquisition of both the SCCmec element and a plasmid encoding the fusidic acid resistance. These changes were associated with human migrations \[[@b22-cm-91-7]\].

ST80 has been identified throughout North Africa, the Middle East, and Europe, with sporadic reports in sub-Saharan Africa \[[@b22-cm-91-7]\].

For European children, PVL is associated with more severe infections, regardless of methicillin resistance \[[@b23-cm-91-7]\].

An European multicentric study shows the USA300 clone is not common among community-infected patients in Europe \[[@b24-cm-91-7]\].

Asia
----

Asia is among the regions with the highest incidence of MRSA in the world. Most reports on the epidemiology of CA-MRSA are from developed countries; the molecular epidemiology of CA-MRSA in Asia is characterized by clonal heterogeneity ([Figure 1](#f1-cm-91-7){ref-type="fig"}), similar to that in Europe \[[@b25-cm-91-7]\], but a dominant clone has not been identified. In certain countries, Vancomycin-intermediate *Staphylococcus aureus* strains and vancomycin-resistant *Staphylococcus aureus* strains are being increasingly identified \[[@b26-cm-91-7],[@b27-cm-91-7]\]. In India, CA-MRSA clones manifest through severe soft tissue and skin infections requiring surgical drainage, bacteremias affecting neonates, especially from lower economic sections, and breast abscesses in lactating mothers \[[@b28-cm-91-7]\].

Africa
------

The distribution of CA-MRSA clones in general is unclear \[[@b29-cm-91-7]\] and the dates are insufficient. The first information about characterization of MRSA in Egypt were published PubMed in 2015 \[[@b30-cm-91-7]\].

ST88-IV African CA-MRSA clone, from Ghana, forms a discrete MRSA lineage, with resistence to β-lactams, tetracycline and chloramphenicol \[[@b6-cm-91-7]\].

South America
-------------

In South America, two predominant CA-MRSA clones have been reported: ST30-SCCmecIV or USA 1100 (first found in Uruguay in 2002 and later in Brazil and Argentina in 2005), and ST8-IV or USA300-Latin American variant (found predominantly in Ecuador and Colombia in 2006--2008) -- [figure 1](#f1-cm-91-7){ref-type="fig"} \[[@b31-cm-91-7],[@b32-cm-91-7]\].

The European ST80 clone is limited to Algeria, Egypt and Tunisia \[[@b29-cm-91-7]\]. In Colombia, several genetic and molecular analyses have shown that the most prevalent CA-MRSA clone is USA300-Latin American \[[@b33-cm-91-7]\]. In Rio de Janeiro, USA300, USA400, USA600, USA800 and USA1100 were identified \[[@b34-cm-91-7]\]. CA-MRSA seems to have a low incidence in Brazil \[[@b35-cm-91-7]\] and Peru \[[@b36-cm-91-7]\].

Conclusions
===========

MRSA epidemiology is changing rapidly due to the continuous development of clones. In turn, it is influenced through the deficient therapeutic management of infectious diseases, through auto-medication, especially in Eastern Europe and Asia. The lowly restricted sales of antibiotics in shops and pharmacies, as well as medical prescribing practices without a laboratory investigation contribute to the development of new MRSA clones with increase resistance to antibiotics.

The epidemiology of MRSA in North America is much better studied and described than the European one. USA300 -- ST8-IV, the predominant North American clone, has become quite well controlled with antibiotics today, but multidrug-resistant phenotypes are emerging. In South America, USA 1100 and USA300-Latin American variants are predominant clones.

In contrast to North America, CA-MRSA in Europe is characterized by bigger clonal heterogeneity. The predominant European clone, ST80-IV, is resistant to kanamycin/amikacin and fusidic acid, and is strongly associated with skin and soft tissue infections. Asia is characterized by clonal heterogeneity, similar to that in Europe, but a dominant clone has not been identified. In India, CA-MRSA clones manifests especially from lower economic sections. For Africa, the dates are insufficient.

The knowledge of clones allows studying antibiotics resistance spectrum for each one, a fact of great importance for medical practice.

Appropriate prevention, risk factors and natural history of staphylococcal infections are not fully elucidated. Therefore, it is necessary to monitor antibiotic resistance, judicious organization of antibiotics prescription and therapy of infectious-contagious disease, medical education of travelers and immigrants.

The molecular diagnosis is performed by highly specialized institutions, but basic laboratory diagnosis is accessible to any hospital and should not be neglected. Genotypic isolate characteristics are not helpful for a clinician caring for an acutely ill patient, but basic microbiological diagnosis can save the patient from death.
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